RETRA exerts anticancer activity in Ewing’s sarcoma cells independent of their TP53 status

• DOI: 10.1016/j.ejca.2015.02.016
• Publication Date: 2015-03-29T18:15:33Z
• Authors: Jürgen Sonnemann; Désirée Grauel; Lisa Blümel; Julia Hentschel; Christian Marx; Annelie Blumrich; Katharina Focke; Sabine Becker; Susan Wittig; Sandra Schinkel; Oliver H. Krämer; James F. Beck
• Keywords: 0303 health sciences; Catechols; Antineoplastic Agents; Bone Neoplasms; Cell Cycle Checkpoints; Sarcoma, Ewing; HCT116 Cells; Thiazoles; 03 medical and health sciences; Mutation; Tumor Cells, Cultured; Humans; Tumor Suppressor Protein p53; Cell Proliferation

Mutant p53 can exert oncogenic activity by inhibitory interaction with p73. The small-molecule RETRA has been described to disrupt this interaction and to suppress carcinoma cells (Kravchenko et al., 2008). RETRA's anticancer activity was restricted to tumour cells bearing mutant p53; it was not active in p53 negative and in p53 wild-type cells. Here, we explored the responsiveness of Ewing's sarcoma (ES) cells with mutant p53 to RETRA. For comparison, we also tested RETRA in p53 null and in p53 wild-type ES cells. We found RETRA to be effective in the three mutant p53 ES cell lines investigated. Strikingly, however, RETRA was similarly effective in the p53-deficient and in the two p53 wild-type ES cell lines examined. RETRA elicited apoptosis, as assessed by flow cytometric analyses of mitochondrial depolarisation and DNA fragmentation, caspase 3/7 activity assay and PARP-1 cleavage immunodetection, and G2/M cell cycle arrest completely independent of the cellular TP53 status. In contrast, various p53-deficient and -proficient carcinoma, osteosarcoma and leukaemia cells were unresponsive to RETRA. RETRA also induced gene expression of p53 target genes PUMA and p21 in ES cells irrespective of their TP53 status. These in vitro findings provide a rationale for an in vivo exploration of RETRA's potential as an effective therapeutic approach for patients with ES.